USANA Health (USNA)
NYSE:USNA
Want to see USNA full AI Analyst Report?
Top Page
USANA Health
(NYSE:USNA)
Select Model
Select Model
Rating:54Neutral
Price Target:
$18.00
▼(-20.11% Downside)
Action:Reiterated
Date:05/21/26
The score is primarily weighed down by compressed profitability and weak free cash flow despite a strong, low-debt balance sheet. Technicals also remain bearish with the stock trading below major moving averages. These negatives are partially offset by a low P/E valuation and a generally constructive earnings call featuring reaffirmed guidance and accelerating omni-channel drivers (notably Rise Wellness), albeit with near-term cost and cash-use headwinds.
Positive Factors
High gross margins & improving revenue
Sustained ~77% gross margin and resumed TTM revenue growth signal durable product-level economics and pricing power. High gross margin provides structural capacity to absorb SG&A investments, fund R&D and retail expansion, and supports margin recovery as sales scale across channels.
Negative Factors
Weak cash generation and low FCF
Very low free cash flow and weak cash conversion reduce the firm's ability to self-fund retail inventory, marketing scale and capex without drawing on reserves or capital markets. Persistent weak cash generation constrains reinvestment and increases sensitivity to execution setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins & improving revenue
Sustained ~77% gross margin and resumed TTM revenue growth signal durable product-level economics and pricing power. High gross margin provides structural capacity to absorb SG&A investments, fund R&D and retail expansion, and supports margin recovery as sales scale across channels.
Read all positive factors
USANA Health (USNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$346.00M
Dividend YieldN/A
Average Volume (3M)173.43K
Price to Earnings (P/E)10.3
Beta (1Y)1.15
Revenue Growth5.67%
EPS Growth-73.96%
CountryUS
Employees1,700
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.47
Shares Outstanding18,463,010
10 Day Avg. Volume170,208
30 Day Avg. Volume173,431
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.68
Price to Sales (P/S)0.39
P/FCF Ratio42.35
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue0.21
Enterprise Value/Gross Profit0.28
Enterprise Value/Ebitda2.52
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.95
Revenue Forecast (FY)$938.74M
USANA Health Business Overview & Revenue Model
Company Description
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that p...
How the Company Makes Money
USANA primarily makes money by selling health and wellness products—most notably dietary supplements and personal care items—through a direct-selling network. Revenue is generated when products are purchased by end customers and/or by the company’...
USANA Health Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 28, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful progress across multiple strategic priorities: sequential recovery in the core nutritional business, strong acceleration and retail traction for Rise Wellness, and international and retail expansion for HYA alongside operational integrations and a sizable R&D pipeline. Near-term pressures include higher customer acquisition costs (HYA), increased SG&A, cash used to support initial retail inventory (Costco), and some uncertainty around retailer cadence and macro risks. On balance, the positive operational momentum, reaffirmed guidance ($925M–$1.0B) and advancing omni-channel mix outweigh the contained near-term costs and risks.Positive Updates
Sequential Growth in Core Nutritional Business
Net sales of $204 million in Q1 2026, representing a 7% sequential increase driven by active customer growth, notably in China following Lunar New Year customer acquisition activity.
Negative Updates
Elevated Customer Acquisition Costs for HYA
HYA has experienced higher short-term customer acquisition costs due to disruptions in the Meta advertising environment beginning in 2025, contributing to increased SG&A versus Q4 and prior year.
Read all updates
Q1-2026 Updates
Positive
Negative
Sequential Growth in Core Nutritional Business
Net sales of $204 million in Q1 2026, representing a 7% sequential increase driven by active customer growth, notably in China following Lunar New Year customer acquisition activity.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 guidance of consolidated net sales of $925 million to $1.0 billion and specifically expects HYA net sales of $140 million to $155 million, with omni‑channel net sales on track to represent >20% of total net sales in 2026 (up from 16% in 2025 and ~1% two years ago); they also noted anticipated margin efficiencies for HYA beginning in 2026 after bringing manufacturing/packaging in‑house and said a modest incremental technology modernization investment will be funded primarily through repurposed resources and operational savings. For context, Q1 results cited on the call included core nutritional net sales of $204 million (up 7% sequentially), HYA net sales of $32 million with 186,000 active monthly subscribers, and Rise Wellness net sales of $14 million (more than 8× prior‑year Q1 and +143% sequential).USANA Health Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
84
Very Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 925.94M | 925.26M | 854.50M | 921.01M | 998.60M | 1.19B |
| Gross Profit | 710.35M | 724.40M | 678.75M | 731.62M | 791.32M | 955.53M |
| EBITDA | 78.34M | 82.07M | 98.86M | 123.11M | 130.22M | 192.89M |
| Net Income | 8.87M | 10.76M | 42.03M | 63.79M | 69.35M | 116.50M |
Balance Sheet | ||||||
| Total Assets | 738.97M | 742.91M | 748.19M | 632.76M | 596.55M | 577.74M |
| Cash, Cash Equivalents and Short-Term Investments | 162.75M | 158.38M | 181.77M | 330.42M | 288.42M | 239.83M |
| Total Debt | 14.00M | 14.00M | 39.20M | 13.21M | 13.78M | 17.30M |
| Total Liabilities | 144.18M | 156.64M | 161.86M | 135.56M | 162.08M | 182.62M |
| Stockholders Equity | 543.55M | 533.10M | 532.11M | 497.20M | 434.47M | 395.12M |
Cash Flow | ||||||
| Free Cash Flow | 2.96M | 8.53M | 50.92M | 56.15M | 93.50M | 108.46M |
| Operating Cash Flow | 16.63M | 22.35M | 60.99M | 70.64M | 103.90M | 121.23M |
| Investing Cash Flow | -8.85M | -10.13M | -213.09M | -11.97M | -12.37M | -14.19M |
| Financing Cash Flow | -29.78M | -40.60M | 9.55M | -14.24M | -30.09M | -181.41M |
USANA Health Technical Analysis
Positive
22.53
Price Trends
18.26
Positive
19.38
Negative
21.90
Negative
Market Momentum
-0.15
Positive
52.39
Neutral
76.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USNA, the sentiment is Positive. The current price of 22.53 is above the 20-day moving average (MA) of 18.58, above the 50-day MA of 18.26, and above the 200-day MA of 21.90, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 52.39 is Neutral, neither overbought nor oversold. The STOCH value of 76.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USNA.
USANA Health Risk Analysis
USANA Health disclosed 43 risk factors in its most recent earnings report. USANA Health reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
USANA Health Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $384.65M | 15.75 | 17.76% | ― | 21.85% | 44.53% | |
68 Neutral | $384.23M | 20.53 | 12.30% | ― | 7.26% | 104.70% | |
63 Neutral | $70.77M | 10.01 | 17.78% | 2.81% | -12.15% | -38.04% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $94.57M | 19.38 | 15.30% | ― | 42.27% | -33.19% | |
60 Neutral | $1.29B | 6.17 | -43.03% | ― | 3.69% | -16.34% | |
54 Neutral | $346.00M | 10.34 | 2.03% | ― | 5.67% | -73.96% |
* Consumer Defensive Sector Average
USNA
USANA Health
18.74
-10.68
-36.30%
HLF
Herbalife
12.43
5.77
86.64%
LWAY
Lifeway Foods
25.17
2.77
12.37%
NATR
Nature's Sunshine Products
21.85
7.02
47.34%
LFVN
LifeVantage
5.61
-6.76
-54.63%
FTLF
FitLife Brands
10.07
-4.37
-30.26%
USANA Health Corporate Events
Executive/Board ChangesShareholder Meetings
USANA Shareholders Approve Directors, Auditor and Compensation
Positive
May 20, 2026
At its Annual Meeting of Shareholders on May 20, 2026, USANA Health reported that approximately 89% of its outstanding common shares were represented in person or by proxy, demonstrating strong investor participation. Shareholders elected eight di...
Business Operations and StrategyFinancial Disclosures
USANA Health Q1 2026 Results Highlight Mixed Performance
Negative
May 5, 2026
USANA Health Sciences reported flat first-quarter 2026 net sales of $250 million versus a year earlier, but net earnings fell 20% to $7.5 million and diluted EPS declined to $0.41, reflecting margin and customer pressures across core operations. C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.